Emerging innovative therapeutic approaches targeting PCSK9 to lower lipids.

08:00 EDT 22nd October 2015 | BioPortfolio

Summary of "Emerging innovative therapeutic approaches targeting PCSK9 to lower lipids."

Statins are established therapies for cardiovascular disease prevention and ezetimibe has recently been shown to modestly reduce cardiovascular events when added to background statin therapy. Yet here remains a clear unmet need for additional therapies aimed at lowering low density lipoprotein cholesterol (LDL-C) to further reduce cardiovascular risk. Multiple strategies targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition have emerged as effective modalities for LDL-C lowering. PCSK-9 monoclonal antibodies are the farthest along in clinical development and alirocumab and evolocumab were approved for clinical use by regulatory agencies in 2015. In addition to robust LDL-C lowering (nearly 50% - 65% from baseline), they improve other lipid parameters as well. Adverse events associated with these medications are minimal. Importantly, they improve clinical cardiovascular disease outcomes, although long term study results are awaited. Cost may be an important limiting factor in their use and we propose 2 possible solutions which can potentially curtail cost. This article is protected by copyright. All rights reserved.


Journal Details

This article was published in the following journal.

Name: Clinical pharmacology and therapeutics
ISSN: 1532-6535


DeepDyve research library

PubMed Articles [21689 Associated PubMed Articles listed on BioPortfolio]

Potentiation of psoriasis-like inflammation by PCSK9.

Psoriasis is a systemic inflammatory disease, associated with metabolic disorders, including high level of low-density lipoprotein(LDL). Proprotein convertase subtilisin/kexin 9 (PCSK9), promoting the...

Recent advances in developing PCSK9 inhibitors for lipid-lowering therapy.

Cardiovascular disease is the major cause of death globally, with hypercholesterolemia being an important risk factor. The PCSK9 represents an attractive therapeutic target for hypercholesterolemia tr...

Efficacy and safety of proprotein convertase subtilisin/kexin 9 inhibitors in people with diabetes and dyslipidaemia.

Diabetic dyslipidaemia, characterized by quantitative, qualitative and kinetic changes in all major circulating lipids, contributes to the increased cardiovascular risk in patients with type 2 diabete...

Small molecules as inhibitors of PCSK9: Current status and future challenges.

Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays an important role in regulating lipoprotein metabolism by binding to low-density lipoprotein receptors (LDLRs), leading to their degradation...

New agents to reduce cholesterol levels: implications for nephrologists.

Statins and ezetimibe effectively reduce the burden of cardiovascular (CV) disease in patients with chronic kidney disease (CKD). Unfortunately, many subjects still die or have CV events despite chole...

Clinical Trials [8002 Associated Clinical Trials listed on BioPortfolio]

Interest of Plasmatic Concentration Dosage of PCSK9 in Coronary Syndrome

PCSK9 (Proprotein convertase subtilisin kexin type 9) is a proconvertase playing the key-role in LDL-Cholesterol (LDLC) metabolism inhibiting the LDL receptor by a post-transcriptional way...

PCSK9 Inhibitors in the Progression of Aortic Stenosis

Investigators plan evaluate whether PCSK9 inhibitors, a medication that can lower lipoprotein(a) and control dyslipidemia, can inhibit the progression of aortic stenosis, through a randomi...

Effects of Corn Oil Plus Vitamin E and B6 on LIpids, PcSk9 and Endothelial Function

This will be a randomized clinical trial carried out on subjects with suboptimal control of cholesterolemia who will consume 30 g per day of a vitaminized corn oil (plus B6 and E vitamins)...

Effect of Alirocumab on Postprandial Hyperlipemia in Patients With Type 2 Diabetes

Proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged over the past decade as a post-transcriptional regulator of the LDL receptor (LDL-R). PCSK9 acts as an endogenous natural ...

Effectiveness of Targeting Food Aid to Malnourished Children Compared to Targeting All Children Under Two Years

The objective of this study is to compare two approaches to targeting donated supplementary food to young children. The study compares the effectiveness of the widely-used curative approac...

Medical and Biotech [MESH] Definitions

Therapeutic approaches that are limited, gradual, or well-established as opposed to radical methods.

Comparison of outcomes, results, responses, etc for different techniques, therapeutic approaches or other inputs.

Combinations of diagnostic or therapeutic substances linked with specific immune substances such as IMMUNOGLOBULINS; MONOCLONAL ANTIBODIES; or ANTIGENS. Often the diagnostic or therapeutic substance is a radionuclide. These conjugates are useful tools for specific targeting of DRUGS and RADIOISOTOPES in the CHEMOTHERAPY and RADIOIMMUNOTHERAPY of certain cancers.

Advanced technology that is costly, requires highly skilled personnel, and is unique in its particular application. Includes innovative, specialized medical/surgical procedures as well as advanced diagnostic and therapeutic equipment.

Clinical, therapeutic and diagnostic approaches to optimal disease management based on individual variations in a patient's genetic profile.

Quick Search


DeepDyve research library

Relevant Topics

Cardiovascular disease (CVD)
Acute Coronary Syndromes (ACS) Blood Cardiovascular Dialysis Hypertension Stent Stroke Vascular Cardiovascular disease (CVD) includes all the diseases of the heart and circulation including coronary heart disease (angina...

Cholesterol is a waxy steroid metabolite found in the cell membranes and transported in the blood plasma. It is an important structural component of mammalian cell membranes, where it is establishes proper membrane permeability and fluidity. Cholesterol ...

Searches Linking to this Article